The aims of our project were to examine whether CD203c is a reliable biomarker of CML basophils and their progenitors, to explore the regulation of expression of CD203c in CML basophils, and to define the prognostic impact of CD203c. This evidence concerns the gene ENPP3 and chronic myelogenous leukemia, BCR-ABL1 positive.